Table III:
Univariable Regressions Predicting Awareness of, Current Use of, or Intention to Use PrEP Among Mexican GSN App Users in 2018–2019
| Variable | Awareness of
PrEP n=2,020 |
Current Use of
PrEP n=1,642 a |
Intention to Use
PrEP n=1,584 b |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes n (%) |
No n (%) |
OR [95% CI] | p value | Yes n (%) |
No n (%) |
OR [95% CI] | p value | Agree n (%) |
Do Not Agree n (%) |
OR [95% CI] | p value | |
| Age | ||||||||||||
| 18–25 | 504 (76.7) | 153 (23.3) | Ref. | Ref. | 12 (2.4) | 492 (97.6) | Ref. | Ref. | 175 (35.6) | 317 (64.4) | Ref. | Ref. |
| 26–30 | 428 (85.6) | 72 (14.4) | 1.80 [1.33–2.46] | < 0.001 | 17 (4.0) | 411 (96.0) | 1.70 [0.80–3.59] | 0.168 | 154 (37.5) | 257 (62.5) | 1.09 [0.83–1.42] | 0.555 |
| 31–40 | 480 (86.0) | 78 (14.0) | 1.87 [1.38–2.52] | < 0.001 | 16 (3.3) | 464 (96.7) | 1.41 [0.66–3.02] | 0.371 | 142 (30.6) | 322 (69.4) | 0.80 [0.61–1.05] | 0.103 |
| 41+ | 230 (75.4) | 75 (24.6) | 0.93 [0.68–1.28] | 0.658 | 13 (5.7) | 217 (94.3) | 2.46 [1.10–5.47] | 0.028 | 70 (32.3) | 147 (67.7) | 0.86 [0.61–1.21] | 0.393 |
| City Population Size | ||||||||||||
| > 1.5 mil. | 1,239 (83.0) | 253 (17.0) | 1.50 [1.05–2.13] | 0.024 | 45 (3.6) | 1,194 (96.4) | 1.93 [0.59–6.30] | 0.273 | 399 (33.4) | 795 (66.6) | 0.74 [0.53–1.05] | 0.093 |
| 500,000–1.5mil. | 246 (76.2) | 77 (23.8) | 0.98 [0.65–1.48] | 0.911 | 10 (4.1) | 236 (95.9) | 2.18 [0.59–8.03] | 0.244 | 80 (33.9) | 156 (66.1) | 0.76 [0.50–1.16] | 0.202 |
| < 500,000 | 157 (76.6) | 48 (23.4) | Ref. | Ref. | 3 (1.9) | 154 (98.1) | Ref. | Ref. | 62 (40.3) | 92 (59.7) | Ref. | Ref. |
| Border State | ||||||||||||
| Yes | 52 (78.8) | 14 (21.2) | 0.85 [0.47–1.55] | 0.597 | 1 (1.9) | 51 (98.1) | 0.53 [0.07–3.88] | 0.530 | 25 (49.0) | 26 (51.0) | 1.90 [1.08–3.31] | 0.025 |
| No | 1,590 (81.4) | 364 (18.6) | Ref. | Ref. | 57 (3.6) | 1,533 (96.4) | Ref. | Ref. | 516 (33.7) | 1,017 (66.3) | Ref. | Ref. |
| HIV Status | ||||||||||||
| Unknown Status | 247 (73.9) | 87 (26.1) | 0.59 [0.45–0.78] | < 0.001 | 7 (2.8) | 240 (97.2) | 0.77 [0.34–1.71] | 0.520 | 98 (40.8) | 142 (59.2) | 1.40 [1.06–1.86] | 0.018 |
| Negative | 1,395 (82.7) | 291 (17.3) | Ref. | Ref. | 51 (3.7) | 1,344 (96.3) | Ref. | Ref. | 443 (33.0) | 901 (67.0) | Ref. | Ref. |
| PrEP Eligible c | ||||||||||||
| Yes | 218 (90.1) | 24 (9.9) | 2.26 [1.46–3.50] | < 0.001 | 47 (21.6) | 171 (78.4) | 35.31 [17.97–69.37] | < 0.001 | 70 (40.9) | 101 (59.1) | 1.39 [1.00–1.92] | 0.048 |
| No | 1,424 (80.1) | 354 (19.9) | Ref. | Ref. | 11 (0.8) | 1,413 (99.2) | Ref. | Ref. | 471 (33.3) | 942 (66.7) | Ref. | Ref. |
| Recent (12 months) STI Testing | ||||||||||||
| Yes | 1,133 (85.3) | 195 (14.7) | 2.09 [1.66–2.62] | < 0.001 | 55 (4.9) | 1,078 (95.1) | 8.61 [2.68–27.64] | < 0.001 | 366 (34.0) | 712 (66.0) | 0.97 [0.78–1.21] | 0.804 |
| No | 509 (73.6) | 183 (26.4) | Ref. | Ref. | 3 (0.6) | 506 (99.4) | Ref. | Ref. | 175 (34.6) | 331 (65.4) | Ref. | Ref. |
| Recent (3 months) Chemsex d | ||||||||||||
| Yes | 52 (80.0) | 13 (20.0) | 0.92 [0.49–1.70] | 0.787 | 6 (11.5) | 46 (88.5) | 3.86 [1.58–9.44] | 0.003 | 22 (47.8) | 24 (52.2) | 1.80 [1.00–3.24] | 0.050 |
| No | 1,590 (81.3) | 365 (18.7) | Ref. | Ref. | 52 (3.3) | 1,538 (96.7) | Ref. | Ref. | 519 (33.8) | 1,019 (66.2) | Ref. | Ref. |
Bolded ORs had a p value of ≤ 0.05
Current use of PrEP includes only those who had heard of PrEP
Intention to use PrEP includes only those who had heard of PrEP who were not currently taking PrEP
Recent PEP use and STI diagnosis, both of which are PrEP eligibility criteria in the PAHO guidelines (29), were used to create the PrEP eligible variable
Survey question specified the following drugs: Mephedrone, GHB/GBL, Ketamine, Methamphetamine. GHB and GBL stand for gamma hydroxybutyrate and gamma butyrolactone, respectively. However only the abbreviation was used in the survey
Abbreviations: OR (odds ratio), CI (confidence interval), PrEP (pre-exposure prophylaxis), Pop. (population), mil. (million), STI (sexually transmitted infection)